4-Phenyl-pyrazolon-(5) | 54945-08-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: 4-Phenyl-pyrazolon-(5)
• 英文别名: 4-Phenyl-1,4-dihydropyrazol-5-one
• CAS: 54945-08-3
• 化学式: C₉H₈N₂O
• 分子量: 160.175
• InChiKey: ZYLZVEUXGDGKKJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis
  申请人：Clerin Valerie

  公开号：US20080009485A1

  公开（公告）日：2008-01-10

  This invention provides methods for the use of substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds in the treating or preventing thrombosis in a mammal, or preventing progression of symptoms of thrombosis.

  这项发明提供了一种使用通式所示的取代吲哚化合物及其药用盐形式的方法。该发明提供了一种在哺乳动物中治疗或预防血栓形成，或预防血栓形成症状进展的化合物使用方法。
• Methods for the Use of Inhibitors of Cytosolic Phospholipase A2
  申请人：McKew John C.

  公开号：US20100035957A1

  公开（公告）日：2010-02-11

  This invention provides methods for the use of substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A 2 enzymes, and for the medical treatment, prevention and inhibition diseases and disorders including asthma, stroke, atherosclerosis, multiple sclerosis, Parkinson's disease, arthritic disorders, rheumatic disorders, central nervous system damage resulting from stroke, central nervous system damage resulting from ischemia, central nervous system damage resulting from trauma, inflammation caused or potentiated by prostaglandins, inflammation caused or potentiated by leukotrienes, inflammation caused or potentiated by platelet activation factor, pain caused or potentiated by prostaglandins, pain caused or potentiated by leukotrienes, and pain caused or potentiated by platelet activation factor.

  本发明提供了代替吲哚化合物的使用方法，其一般式为：及其药学上可接受的盐形式。本发明提供了将这些化合物用作各种磷脂酶酶活性的抑制剂的使用方法，特别是磷脂酶A2酶，以及用于医疗治疗、预防和抑制包括哮喘、中风、动脉粥样硬化、多发性硬化症、帕金森病、关节炎性疾病、风湿性疾病、中风引起的中枢神经系统损伤、缺血引起的中枢神经系统损伤、创伤引起的中枢神经系统损伤、由前列腺素引起或增强的炎症、由白三烯引起或增强的炎症、由血小板活化因子引起或增强的炎症、由前列腺素引起或增强的疼痛、由白三烯引起或增强的疼痛以及由血小板活化因子引起或增强的疼痛等疾病和障碍的使用方法。
• LIQUID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS
  申请人：Donahue Frances Anne

  公开号：US20100069385A1

  公开（公告）日：2010-03-18

  The present invention is directed to liquid formulations of inhibitors of phospholipase enzymes, such as cytosolic PLA2, compositions containing the same and processes for manufacture thereof.
• US7605156B2
  申请人：——

  公开号：US7605156B2

  公开（公告）日：2009-10-20
• US7906548B2
  申请人：——

  公开号：US7906548B2

  公开（公告）日：2011-03-15